REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III
Phase I/IIa data for a single dose of REGENEXBIO’s gene therapy, RGX-314, shows promise for treating wet age-related macular degeneration.
Phase I/IIa data for a single dose of REGENEXBIO’s gene therapy, RGX-314, shows promise for treating wet age-related macular degeneration.
DNA analyses reveal viruses have infected red algae—and spurred evolution—for at least 1.5 billion years
Animals use superior integration of inferior components, a bioinspiration principle for transformative advances in robotics.
Solvias says its new center complements its biologics and CGT sites in Europe and expands its testing capabilities in the United States.
Protein that senses viruses becomes overactive in autoimmune disease
Metabolism of autism reveals developmental origins.
Too often, data collected from wearables and monitoring devices adds to the burden on healthcare professionals. Help in the form of a new information…
C100 injections led to synergistic therapeutic effects with anti-PD1 immune checkpoint blockade (ICB) therapy in a preclinical model.
Perturbation of X-chromosome inactivation, a female-specific process, induces signs of lupus, a disease that mostly affects women.
Citing aging infrastructure at Antarctic base, agency declines to advance plan to build microwave telescope array
Capsida plans to advance its gene therapy program into clinical development in the first half of 2025.